The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Dexcom has rounded up its celebrity spokespeople for World Diabetes Day, putting singer Nick Jonas at the center of a ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Thursday’s appointment from President-elect Donald Trump made it official: noted vaccine skeptic Robert Francis Kennedy Jr.

After pledging to allow politician and vaccine skeptic Robert Francis Kennedy Jr. | Trump's appointment follows his ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing its work to improve awareness of and education around the rare disease.

A strand of Merz Pharmaceuticals’ star-studded promotion of the anti-wrinkle drug Xeomin has landed it a reprimand from the ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...